MECHANISM OF ACTION AND THERAPEUTIC BENEFIT OF RIFAXIMIN IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: A NARRATIVE REVIEW

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with a multifactorial pathophysiology.The gut microbiota differs between patients with IBS and healthy individuals.After a bout of acute gastroenteritis, postinfection IBS may result in up to approximately 10% of those affected.Small intestinal bacterial overgrowth (SIB

A central question to biology is how pathogenic bacteria initiate acute or chronic infections.Here we describe a genetic program for cell-fate decision in the opportunistic human pathogen Staphylococcus aureus, which generates the phenotypic bifurcation of the cells into two genetically Fleece Shirts identical but different cell types during the co